ResearcherHarvard UniversityActive in the last 2 years

Stanley W. Ashley

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7632-5037; OpenAlex author ID A5007024286. Sources: OpenAlex.

Their work

Papers: 16 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 7 papers · 2024: 1 paper · 2025: 3 papers

Papers 16

Editor's Note: A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0886 ↗
Retraction: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2. Co-author DOI 10.1158/0008-5472.can-25-0887 ↗
Editor's Note: RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresist… Co-author DOI 10.1158/1078-0432.ccr-25-0820 ↗
Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocarcinoma: National Cancer Database Analysi… Co-author DOI 10.7759/cureus.73524 ↗
Withdrawal: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. Co-author DOI 10.1016/j.jbc.2023.105007 ↗
Retraction notice to Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase (RRM2): a novel therapeutic strategy in pancre… Co-author DOI 10.1016/j.surg.2023.01.008 ↗
Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity [Surgery -September 2004, Pages… Co-author DOI 10.1016/j.surg.2023.01.009 ↗
Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s41388-023-02625-6 ↗
Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-023-02626-5 ↗
Retraction Note: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Co-author DOI 10.1038/s41388-023-02627-4 ↗
Editorial Expression of Concern: Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Co-author DOI 10.1038/s41388-023-02784-6 ↗
Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. Co-author DOI 10.1177/00031348211011129 ↗
Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection. Co-author DOI 10.1177/0003134821991962 ↗
Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm11164866 ↗
Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. Co-author DOI 10.1016/j.jss.2020.07.073 ↗
Comment on Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. First author DOI 10.1097/sla.0000000000003667 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.